Moving lentiviral-based gene therapy into a first-in-man CF trial

Moving lentiviral-based gene therapy into a first-in-man CF trial

Detaylı Bibliyografya
Asıl Yazarlar:	Griesenbach, D, Alton, E, Beekman, J, Boyd, A, Chan, M, Davies, J, Davies, L, Davidson, H, Dekkers, F, Gea-Sorli, S, Gill, D, Hasegawa, M, Higgins, T, Hyndman, L, McLachlan, G, Inoue, M, Hyde, S, Moran, C, Meng, C, Paul-Smith, M, Pringle, I, Pytel, K, Rodriguez-Martinez, A, Stevenson, B, Tsugumine, S
Materyal Türü:	Conference item
Dil:	English
Baskı/Yayın Bilgisi:	Wiley 2015

Benzer Materyaller

Preparation for a first-in-man lentivirus trial in cystic fibrosis patients
Yazar:: Griesenbach, U, ve diğerleri
Baskı/Yayın Bilgisi: (2016)

Production of SIV-F/HN: a new Lentivirus vector for CF gene therapy
Yazar:: Hyde, S, ve diğerleri
Baskı/Yayın Bilgisi: (2015)

TOXICOLOGY STUDIES IN SUPPORT OF THE UK CF GENE THERAPY CONSORTIUM'S MULTI-DOSE CLINICAL TRIAL
Yazar:: Griesenbach, U, ve diğerleri
Baskı/Yayın Bilgisi: (2011)

Genetic medicines for CF: Hype versus reality
Yazar:: Alton, E, ve diğerleri
Baskı/Yayın Bilgisi: (2016)

Preparation for a first-in-man lentivirus trial in patients with cystic fibrosis.
Yazar:: Alton, E, ve diğerleri
Baskı/Yayın Bilgisi: (2016)

EVALUATION OF SAFETY AND GENE EXPRESSION WITH A SINGLE DOSE OF PGM169/GL67A ADMINISTERED TO THE NOSE AND LUNG OF INDIVIDUALS WITH CF: THE UK CF GENE THERAPY CONSORTIUM "PILOT STUDY"
Yazar:: Davies, J, ve diğerleri
Baskı/Yayın Bilgisi: (2009)

SAFETY AND EXPRESSION OF A SINGLE DOSE OF LIPID-MEDIATED CFTR GENE THERAPY TO THE UPPER AND LOWER AIRWAYS OF PATIENTS WITH CF
Yazar:: Davies, J, ve diğerleri
Baskı/Yayın Bilgisi: (2011)

Update on the UK CF Gene Therapy Consortium Multidoes, non-viral, gene therapy trial
Yazar:: Alton, E, ve diğerleri
Baskı/Yayın Bilgisi: (2012)

UPDATE ON THE UK CF GENE THERAPY CONSORTIUM MULTIDOSE, NON-VIRAL, GENE THERAPY TRIAL
Yazar:: Alton, E, ve diğerleri
Baskı/Yayın Bilgisi: (2012)

UPDATE ON THE UK CF GENE THERAPY CONSORTIUM MULTIDOSE, NON-VIRAL, GENE THERAPY TRIAL
Yazar:: Alton, E, ve diğerleri
Baskı/Yayın Bilgisi: (2012)

EVALUATION OF SAFETY AND GENE EXPRESSION WITH A SINGLE DOSE OF PGM169/GL67A ADMINISTERED TO THE NOSE AND LUNG OF INDIVIDUALS WITH CYSTIC FIBROSIS: THE UK CF GENE THERAPY CONSORTIUM "PILOT STUDY''
Yazar:: Davies, J, ve diğerleri
Baskı/Yayın Bilgisi: (2009)

A PHASE 2B DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF NON-VIRAL MEDIATED GENE THERAPY FOR CF
Yazar:: Alton, E, ve diğerleri
Baskı/Yayın Bilgisi: (2013)

Towards a first-in-human trial with a pseudotyped lentivirus
Yazar:: Alton, EW, ve diğerleri
Baskı/Yayın Bilgisi: (2020)

OPTIMISATION OF MOLECULAR ASSAYS FOR CLINICAL TRIAL OF GL67A/PDNA DELIVERY TO NOSE AND LUNG OF CF PATIENTS
Yazar:: Sumner-Jones, S, ve diğerleri
Baskı/Yayın Bilgisi: (2009)

Recombinant Sendai virus vector to evaluate vector distribution in a large animal model of lung gene transfer
Yazar:: McLachlan, G, ve diğerleri
Baskı/Yayın Bilgisi: (2004)

DEVELOPMENT, PRODUCTION AND EVALUATION OF CLINICAL GRADE CFTR EXPRESSION PLASMID FOR CF LUNG GENE THERAPY
Yazar:: Gill, DR, ve diğerleri
Baskı/Yayın Bilgisi: (2010)

Gene therapy for respiratory diseases; progress and a changing context
Yazar:: Alton, EWFW, ve diğerleri
Baskı/Yayın Bilgisi: (2020)

597: Protocol development for mouse toxicology studies using lentiviral gene therapy
Yazar:: Sinadinos, A, ve diğerleri
Baskı/Yayın Bilgisi: (2021)

REPEAT ADMINISTRATION OF GL67A/PGM169 IS FEASIBLE, SAFE, AND PRODUCES ENDOGENOUS LEVELS OF CFTR EXPRESSION AFTER 12 DOSES
Yazar:: Alton, E, ve diğerleri
Baskı/Yayın Bilgisi: (2012)

Toxicology study assessing efficacy and safety of repeated administration of lipid/DNA complexes to mouse lung.
Yazar:: Alton, E, ve diğerleri
Baskı/Yayın Bilgisi: (2014)

Cumulative CFTR expression following repeated aerosol delivery of non-viral pGM169/GL67A formulation to mouse lung
Yazar:: Alton, E, ve diğerleri
Baskı/Yayın Bilgisi: (2012)

Toxicology study assessing efficacy and safety of repeated administration of lipid/DNA complexes to mouse lung
Yazar:: Alton, E, ve diğerleri
Baskı/Yayın Bilgisi: (2014)

Development of lentiviral vector respiratory tract dosing methods in anticipation of rodent GLP toxicology assessment
Yazar:: Sinadinos, A, ve diğerleri
Baskı/Yayın Bilgisi: (2021)

The lung as a factory to produce secreted intrapulmonary and circulatory proteins
Yazar:: Paul-Smith, M, ve diğerleri
Baskı/Yayın Bilgisi: (2017)

EXERCISE CAPACITY AND PHYSICAL ACTIVITY IN PATIENTS WITH CF: DATA FROM THE UK CF GENE THERAPY CONSORTIUM (UKCFGTC) 'RUN-IN' STUDY
Yazar:: Saunders, C, ve diğerleri
Baskı/Yayın Bilgisi: (2010)

UKCF gene therapy consortium tracking study: Sputum and serum calprotectin are useful novel measurements in CF exacerbation
Yazar:: Gray, R, ve diğerleri
Baskı/Yayın Bilgisi: (2007)

The murine lung as a factory to produce secreted intrapulmonary and circulatory proteins
Yazar:: Paul-Smith, M, ve diğerleri
Baskı/Yayın Bilgisi: (2018)

3-STEP TAQMAN RT-PCR: ULTIMATE MESSENGER RNA DETECTION SENSITIVITY FOR CF GENE THERAPY CLINICAL TRIALS
Yazar:: McCormick, D, ve diğerleri
Baskı/Yayın Bilgisi: (2009)

Pre-existing immunity to human parainfluenza virus (hPIV) does not affect rSIV.F/HN-mediated transduction efficiency
Yazar:: Pytel, K, ve diğerleri
Baskı/Yayın Bilgisi: (2016)

SAFETY AND EXPRESSION OF A SINGLE DOSE OF LIPID-MEDIATED CFTR GENE THERAPY TO THE UPPER AND LOWER AIRWAYS OF PATIENTS WITH CYSTIC FIBROSIS
Yazar:: Davies, G, ve diğerleri
Baskı/Yayın Bilgisi: (2011)

Assessment of selected media supplements to improve F/HN lentiviral vector production yields
Yazar:: Gélinas, J, ve diğerleri
Baskı/Yayın Bilgisi: (2017)

Pre-clinical evaluation of three non-viral gene transfer agents for cystic fibrosis after aerosol delivery to the ovine lung.
Yazar:: McLachlan, G, ve diğerleri
Baskı/Yayın Bilgisi: (2011)

Cholesterol as an enhancer of lentiviral vector production in serum-free transient transfection
Yazar:: Gelinas, J, ve diğerleri
Baskı/Yayın Bilgisi: (2013)

LONGITUDINAL ASSESSMENT OF BIOMARKERS FOR CLINICAL TRIALS OF NOVEL THERAPEUTIC AGENTS: THE RUN-IN STUDY
Yazar:: Alton, E, ve diğerleri
Baskı/Yayın Bilgisi: (2010)

A method for assessing the distribution of eGFP expressing cells in the mouse lung following lentiviral vector transduction
Yazar:: Munday, R, ve diğerleri
Baskı/Yayın Bilgisi: (2018)

A randomised, double-blind, placebo-controlled phase IIB clinical trial of repeated application of gene therapy in patients with cystic fibrosis
Yazar:: Alton, E, ve diğerleri
Baskı/Yayın Bilgisi: (2013)

A randomised, double-blind, placebo-controlled phase IIB clinical trial of repeated application of gene therapy in patients with cystic fibrosis.
Yazar:: Alton, E, ve diğerleri
Baskı/Yayın Bilgisi: (2013)

Large-scale, high-throughput production of lentiviral vectors for multiple disease applications
Yazar:: Ashworth, R, ve diğerleri
Baskı/Yayın Bilgisi: (2018)

Recombinant Sendai virus vector to evaluate vector distribution in a large animal model of lung gene transfer
Yazar:: McLachlan, G, ve diğerleri
Baskı/Yayın Bilgisi: (2004)

LONGITUDINAL ASSESSMENT OF BIOMARKERS FOR CLINICAL TRIALS OF NOVEL THERAPEUTIC AGENTS; THE RUN-IN STUDY
Yazar:: Alton, E, ve diğerleri
Baskı/Yayın Bilgisi: (2010)